2026 NIAID DMID Omnibus Broad Agency Announcement
ID: HHS-NIH-NIAID-BAA2025-1Type: Presolicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH NIAIDBETHESDA, MD, 20892, USA

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)

PSC

HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH (AN12)

Original Source

https://sam.gov/opp/f450cc7fee4b4df781f7b8647bf9b943/view
Timeline
    Description

    The Department of Health and Human Services, through the National Institutes of Health (NIH) and specifically the National Institute of Allergy and Infectious Diseases (NIAID), is soliciting proposals for the 2026 NIAID DMID Omnibus Broad Agency Announcement (BAA) aimed at advancing medical countermeasures against infectious diseases. This opportunity encompasses two primary research areas: the development of therapeutics, vaccines, and diagnostics for antimicrobial-resistant pathogens, and the creation of direct acting antivirals targeting viruses with pandemic potential. The initiative is critical for enhancing public health responses to emerging infectious threats and includes funding estimates of up to $8.5 million for Research Area 001 and $20 million for Research Area 002, with proposals due to be submitted online via the NIAID electronic Contract Proposal Submission (eCPS) platform, starting around November 22, 2024. For further inquiries, interested parties may contact Swee L. Teo at teosl@niaid.nih.gov or Brian Madgey at brian.madgey@nih.gov.

    Files
    Title
    Posted
    Pre-solicitation Notice - BAA2025-1 Final.pdf
    The 2026 NIAID Omnibus Broad Agency Announcement (HHS-NIH-NIAID-BAA2025-1) seeks proposals for research to enhance medical countermeasures against infectious diseases. NIAID, under the NIH, is soliciting innovative projects in two main research areas. Research Area 001 focuses on therapeutics, vaccines, and diagnostics for antimicrobial-resistant bacterial and fungal pathogens. It comprises three topics: developing therapeutics for severe infections caused by specified pathogens, advancing vaccine candidates against ESKAPE bacterial pathogens, and creating diagnostic technologies for identifying fungal infections. Research Area 002 emphasizes the development of direct acting antivirals targeting viruses with pandemic potential, requiring proposals for new chemical entities that reduce viral load in early disease stages. Funding estimates range from $8.5 million for Research Area 001 to $20 million for Research Area 002, with expectations of one to two and three to four awards, respectively, each contract lasting up to five years. Proposals will be evaluated independently based on technical objectives set by the NIAID, with no guarantee of contract awards. Submission guidelines mandate online proposals via the NIAID electronic platform, with no provision for acceptance through email or fax. The announcement will be available around November 22, 2024, signaling the government's commitment to advancing public health through innovative research.
    Lifecycle
    Title
    Type
    2026 NIAID DMID Omnibus Broad Agency Announcement
    Currently viewing
    Presolicitation
    Similar Opportunities
    NIAID CLINICAL PRODUCTS CENTER (CPC)
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking proposals for a contract to provide pharmacy and pharmaceutical oversight for clinical trials, both nationally and internationally. The primary objective of this contract is to ensure the integrity of study products, participant safety, and compliance with pharmacy and pharmaceutical regulations throughout various NIH-funded clinical trials. This opportunity is critical for maintaining high standards in public health research, as it encompasses a wide range of services including product management, regulatory document maintenance, and clinical laboratory testing. Proposals are due by January 17, 2025, with the contract expected to commence on April 1, 2026, and run through March 31, 2027, potentially extending through 2033. Interested parties can contact Deborah Blyveis at blyveisd@niaid.nih.gov or Emily Bannister at emily.bannister@nih.gov for further information.
    Rapid Pandemic Influenza and Emergency Infectious Disease Vaccine Development and Response Capability
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response (BARDA), is seeking proposals for the "Rapid Pandemic Influenza and Emergency Infectious Disease Vaccine Development and Response Capability" through a Special Notice. The objective of this procurement is to establish a long-term partnership focused on developing a flexible and rapid response capability for vaccine development against pandemic influenza and other priority pathogens, initially emphasizing influenza mRNA vaccine development. This initiative is critical for enhancing the nation's preparedness and response to emerging infectious diseases, ensuring readiness to pivot quickly in the face of public health threats. Interested parties can access the full Request for Project Proposals and additional consortium information at www.rrpv.org, and inquiries can be directed to Rebecca Harmon at rebecca.harmon@ati.org.
    BARDA DRIVe EZ-BAA (EZBAA - 22-100-SOL-00003)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Office of Biomedical Advanced Research and Development Authority (BARDA), is soliciting proposals under the Easy Broad Agency Announcement (EZ-BAA) BAA-22-100-SOL-00003, which focuses on innovative medical countermeasures (MCMs) to address public health emergencies. The initiative invites submissions across various Areas of Interest (AOIs), including but not limited to vaccine development, diagnostics, and therapeutics for infectious diseases and chemical threats. This program is crucial for enhancing the nation's preparedness against health security threats, particularly in light of recent global health challenges. Interested parties must register on SAM.gov and adhere to specific submission deadlines, with multiple awards anticipated based on scientific merit and funding availability. For further inquiries, respondents can contact Aarati Singal or Lara Emmons at DRIVeAcquisitions@hhs.gov.
    Chemistry, Manufacturing and Controls and Related Services for Development of Drug Substances
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is soliciting proposals for Chemistry, Manufacturing, and Control (CMC) services related to the development of drug substances under RFP number 75N95024R00094. The primary objective is to secure high-quality drug substances to support preclinical and Investigational New Drug (IND)-enabling studies, ensuring compliance with current Good Manufacturing Practices (cGMP) and federal regulations. This initiative is crucial for advancing therapeutic innovations and facilitating collaborations in drug development, with a total funding amount of up to $49.7 million over the contract period from September 1, 2025, to May 14, 2031. Interested parties must submit their proposals by December 3, 2024, and can direct inquiries to primary contact Samson Shifaraw at samson.shifaraw@nih.gov or secondary contact Valerie Whipple at valerie.whipple@nih.gov.
    IMMUNE EPITOPE DATABASE AND ANALYSIS PROGRAM
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is soliciting proposals for the Immune Epitope Database and Analysis Program, aimed at enhancing research capabilities related to infectious diseases, allergies, and autoimmunity. The program seeks to provide a comprehensive resource for researchers to explore data on antibody and T-cell epitopes, with a focus on maintaining high standards of compliance and transparency in research practices. Proposals are due by November 19, 2024, with a base performance period from October 15, 2025, to October 14, 2026, and potential extensions for up to four additional years. Interested parties can contact Brandon de White at whitebra@niaid.nih.gov or Tom Bahrami at bahramit@niaid.nih.gov for further information.
    FY25 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Food and Drug Administration (FDA), is soliciting proposals for the FY25 Broad Agency Announcement (BAA) aimed at advancing research and development in regulatory science. This initiative seeks to acquire innovative research proposals that enhance the FDA's mission to protect public health by modernizing the evaluation of FDA-regulated products and improving post-market surveillance. Eligible applicants, including private organizations and academic institutions, are encouraged to submit proposals that address critical knowledge gaps and align with FDA priorities, with a submission deadline for full proposals set for February 24, 2025. Interested parties can contact Ian Weiss at Ian.Weiss@fda.hhs.gov or by phone at 301-796-5728 for further information.
    Decentralized Clinical Operations for Healthcare and Research (D-COHRe) Partnership Solicitation
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services (HHS) is seeking proposals for the Decentralized Clinical Operations for Healthcare and Research (D-COHRe) Partnership Solicitation, aimed at establishing partnerships with organizations that provide decentralized healthcare services or have decentralized clinical research capabilities. The initiative focuses on enhancing clinical trial capabilities and medical countermeasure (MCM) development, particularly during public health emergencies, by building a sustainable decentralized clinical research infrastructure. With an anticipated funding amount of up to $100 million distributed over a five-year performance period, proposals are due by December 9, 2024, at 12:00 PM EST. Interested parties can direct inquiries to LaunchOfficeContracting@hhs.gov for proposal submissions and additional information.
    Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)
    Active
    Health And Human Services, Department Of
    Solicitation HEALTH AND HUMAN SERVICES, DEPARTMENT OF Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA) is seeking proposals for various health research and development services. This opportunity is typically used for experimental development and healthcare services. The place of performance is in the USA. For more information, please contact BARDA-BAA@hhs.gov. The deadline for proposal submission is September 25, 2028, at 4:30 PM Eastern Time.
    NIAID PROFESSIONAL, SCIENTIFIC AND TECHNICAL SUPPORT SERVICES (PSTSS)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH) NIAID, is seeking proposals for Professional, Scientific, and Technical Support Services (PSTSS) to assist with various research initiatives, including basic, translational, and clinical research, as well as vaccine development and laboratory research across multiple biosafety levels. The procurement aims to secure specialized expertise to enhance the effectiveness of ongoing and future research efforts critical to public health. Proposals are due by December 16, 2024, with the contract period set to commence on June 1, 2025, and potentially extend to November 30, 2030, with a total funding cap of $3 billion across all awarded contracts. Interested parties can reach out to Rosemary Gomes at Rosemary.Gomes@nih.gov or Kristel Turansky at Kristel.Turansky@nih.gov for further information.
    RRPV Solicitation Summary: NextGen Oral Formulation Vaccines for COVID-19
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority (BARDA), is soliciting proposals for the "NextGen Oral Formulation Vaccines for COVID-19" under the Rapid Response Partnership Vehicle (RRPV) Consortium. The objective of this initiative is to advance oral vaccine platforms and technologies into a proof-of-concept Phase 1 clinical trial, enhancing understanding of their potential and improving COVID-19 solutions to bolster preparedness against future health security threats. This effort is critical in the ongoing response to the COVID-19 pandemic and aims to develop innovative vaccine solutions. Interested parties should note that the proposal submission deadline has been extended to November 15, 2024, and can contact Rebecca Harmon at rebecca.harmon@ati.org for further information.